Compare Cassava Sciences Inc (FLNA) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs UBS Group AG Registered Ordinary Shares — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while UBS Group AG Registered Ordinary Shares trades at $47.37 (market cap $144.63B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 3670.8× Cassava Sciences Inc's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.32% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and UBS Group AG Registered Ordinary Shares for 0 Days on average.
| FLNA | UBS | |
|---|---|---|
Market Cap | $39.40M | $144.63B |
Volume | 759,018 | 1,746,723 |
Sector | Health | Financials |
52-Week High | $4.64 | $55.72 |
52-Week Low | $0.68 | $36.41 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | -$43.28M | $311.50B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
